- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
Patent holdings for IPC class C07K 16/32
Total number of patents in this class: 4069
10-year publication summary
|
282
|
375
|
312
|
324
|
335
|
359
|
345
|
322
|
337
|
326
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Genentech, Inc. | 4008 |
162 |
| Hoffmann-La Roche Inc. | 3534 |
113 |
| F. Hoffmann-La Roche AG | 7934 |
85 |
| Zymeworks Inc. | 263 |
49 |
| Daiichi Sankyo Company, Limited | 1880 |
48 |
| Mayo Foundation for Medical Education and Research | 3286 |
45 |
| Merus N.V. | 225 |
45 |
| Amgen Inc. | 4163 |
44 |
| Genmab A/S | 440 |
43 |
| The Trustees of the University of Pennsylvania | 4376 |
41 |
| Regeneron Pharmaceuticals, Inc. | 4426 |
39 |
| Sanofi | 4122 |
37 |
| Memorial Sloan-Kettering Cancer Center | 1979 |
34 |
| Centre National de La Recherche Scientifique | 10666 |
33 |
| Dragonfly Therapeutics, Inc. | 131 |
30 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3369 |
28 |
| Sutro Biopharma, Inc. | 172 |
28 |
| Board of Regents, The University of Texas System | 5927 |
27 |
| Novartis AG | 10626 |
26 |
| Immatics Biotechnologies GmbH | 1158 |
25 |
| Other owners | 3087 |